Home >> EPZ004777
Related Products
EPZ004777 DOT1L inhibitor

Catalog No.A4170
Size Price Stock Qty
10mM (in 1mL DMSO)
$130.00
In stock
5mg
$110.00
In stock
50mg
$550.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

EPZ004777

Protocol

Cell experiment[1]:

Cell lines

Human leukaemia cell line MV4;11 and Molm13 cells

Preparation method

The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

96 h, 10 μM

Applications

EPZ004777 is a specific and potent inhibitor of DOT1L with IC50 values of 400 pM in a radionuclide homogeneous assay. It selectively kills mixed lineage leukaemia cells, in which DOT1L interacts with oncogenic MLL fusion protein and is unconventionally localized.

Animal experiment [2]:

Animal models

Eight-week-old C57BL/6 mice

Dosage form

Mice were implanted with osmotic pumps loaded with vehicle(15% ethanol, 50% PEG300, 35% water) or EPZ004777 at 150 mg/ml. One week later, osmotic pumps were replaced and retained for another week.

Application

EPZ004777 is well tolerated and no obvious toxicity is observed in mice. EPZ004777 has both antitumor and pharmacodynamic efficacy in the mouse xenograft model of MLL leukemia.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Yu W, Chory E J, Wernimont A K, et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors[J]. Nature communications, 2012, 3: 1288.

[2]. Daigle S R, Olhava E J, Therkelsen C A, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor[J]. Cancer cell, 2011, 20(1): 53-65.

EPZ004777 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

EPZ004777 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1338466-77-5 SDF Download SDF
Chemical Name 1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea
Canonical SMILES CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)CC2C(C(C(O2)N3C=CC4=C3N=CN=C4N)O)O
Formula C28H41N7O4 M.Wt 539.67
Solubility >27mg/mL in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

EPZ004777 is a specific small-molecule H3K79 methyltransferase DOT1L inhibitor that potently inhibits DOT1L in a radionuclide homogeneous assay with the half maximal inhibition concentration IC50 value of 400 pM and selectively kills a variety of MLL-rearranged leukemia cells, including an MLL-AF4 leukemia cell line MV4-11 and an MLL-AF9 leukemia cell line MOLM13 [1 & 2].

EPZ004777 has also been found to selectively inhibit the proliferation of MLL-AF10 and CALM-AF10 transformed cells in a dose dependent manner (IC50: 0.1 μM to 1 μM), in which the mRNA expression levels of two hallmark leukemogenic genes (Hoxa9 and Meis1) are suppressed by EPZ004777 in a concentration dependent manner [2].

Reference

References:
[1] Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288. doi: 10.1038/ncomms2304.
[2] Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr;27(4):813-22. doi: 10.1038/leu.2012.327. Epub 2012 Nov 9.